Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : SIGA Technologies
Deal Size : Undisclosed
Deal Type : Agreement
SIGA Amends International Agreement for Oral TPOXX® Growth
Details : SIGA will lead international promotions for oral TPOXX, an FDA-approved drug for smallpox, while maintaining its contractual relationship with Meridian to ensure continuity for key customers.
Product Name : Tpoxx
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 04, 2024
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : SIGA Technologies
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : ASPR
Deal Size : $9.9 million
Deal Type : Agreement
Details : Under the agreement, Meridian will supply DuoDote to the Administration for Strategic Preparedness and Response within the United States. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent anti...
Product Name : DuoDote
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 14, 2023
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : ASPR
Deal Size : $9.9 million
Deal Type : Agreement
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Public Health Agency of Canada
Deal Size : $3.4 million
Deal Type : Collaboration
Details : Public Health Agency of Canada has contracted Meridian Medical Technologies for the purchase up to approximately $33 million of oral TPOXX® within five years. TPOXX® is an orally administered antiviral drug for the treatment of human smallpox disease c...
Product Name : Tpoxx
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 13, 2021
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Public Health Agency of Canada
Deal Size : $3.4 million
Deal Type : Collaboration